ResMed (RMD) Financials

$208.08 -0.90 (-0.43%)

As of 03:02 PM Eastern

Annual Income Statements for ResMed

This table shows ResMed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	353	352	342	316	405	622	475	779	898	1,021	1,401
Consolidated Net Income / (Loss)	353	352	342	316	405	622	475	779	898	1,021	1,401
Net Income / (Loss) Continuing Operations	353	352	342	316	405	622	475	779	898	1,021	1,401
Total Pre-Tax Income	436	440	419	521	519	733	884	960	1,102	1,265	1,678
Total Operating Income	409	429	426	542	579	810	904	1,000	1,132	1,320	1,685
Total Gross Profit	1,011	1,066	1,202	1,335	1,494	1,718	1,839	2,024	2,356	2,655	3,055
Total Revenue	1,679	1,839	2,067	2,340	2,607	2,957	3,197	3,578	4,223	4,685	5,146
Total Cost of Revenue	668	772	865	1,005	1,113	1,239	1,358	1,554	1,867	2,030	2,091
Operating Cost of Revenue	668	772	865	1,005	1,113	1,239	1,358	1,554	1,867	2,030	2,091
Total Operating Expenses	602	638	776	793	915	908	935	1,024	1,224	1,335	1,370
Selling, General & Admin Expense	479	488	554	600	645	677	670	738	874	917	991
Research & Development Expense	115	119	144	155	181	202	225	254	288	308	331
Amortization Expense	8.67	24	47	19	32	30	31	31	42	47	45
Total Other Income / (Expense), net	27	11	-7.06	-21	-60	-77	-20	-40	-30	-55	-7.80
Interest & Investment Income	26	17	17	16	-14	-25	-11	-31	-55	-48	3.64
Other Income / (Expense), net	6.25	4.96	4.10	-8.54	-11	-12	15	-9.01	24	-7.54	-16
Income Tax Expense	83	87	76	206	114	111	409	181	204	244	277
Basic Earnings per Share	$2.51	$2.51	$2.42	$2.21	$2.83	$4.31	$3.27	$5.34	$6.12	$6.94	$9.55
Weighted Average Basic Shares Outstanding	140.47M	140.24M	141.36M	142.76M	143.11M	144.34M	145.31M	146.07M	146.77M	147.02M	146.72M
Diluted Earnings per Share	$2.47	$2.49	$2.40	$2.19	$2.80	$4.27	$3.24	$5.30	$6.09	$6.92	$9.51
Weighted Average Diluted Shares Outstanding	142.69M	141.67M	142.45M	143.99M	144.48M	145.65M	146.45M	147.04M	147.46M	147.55M	147.34M
Weighted Average Basic & Diluted Shares Outstanding	140.60M	140.40M	141.40M	142.80M	143M	144.90M	145.68K	146.42M	147.07M	146.93M	146.41M
Cash Dividends to Common per Share	$1.12	$1.20	$1.32	$1.40	$1.48	$1.56	$1.56	$1.68	$1.76	$1.92	$2.12

This table shows ResMed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	219	209	300	292	311	345	365	380	349	393	399
Consolidated Net Income / (Loss)	219	209	300	292	311	345	365	380	349	393	399
Net Income / (Loss) Continuing Operations	219	209	300	292	311	345	365	380	349	393	399
Total Pre-Tax Income	272	259	375	358	383	418	418	458	447	496	502
Total Operating Income	289	275	375	381	387	417	426	455	447	492	500
Total Gross Profit	600	647	693	716	717	751	766	820	821	879	891
Total Revenue	1,102	1,163	1,197	1,223	1,225	1,282	1,292	1,348	1,336	1,423	1,431
Operating Revenue	1,102	1,163	1,197	1,223	-	-	-	-	1,336	1,423	1,431
Total Cost of Revenue	502	516	504	508	507	531	525	528	515	544	540
Operating Cost of Revenue	502	516	504	508	507	531	525	528	515	544	540
Total Operating Expenses	311	372	318	334	330	334	340	366	374	387	391
Selling, General & Admin Expense	223	222	230	242	239	242	245	265	259	278	286
Research & Development Expense	76	74	77	81	80	81	84	86	87	91	94
Amortization Expense	12	12	11	11	11	11	11	12	12	12	11
Other Operating Expenses / (Income)	-	-	-	-	-	-	-	-	0.00	0.00	0.00
Restructuring Charge	-	64	0.00	-	-	-	0.00	-	16	5.94	0.00
Total Other Income / (Expense), net	-17	-16	0.84	-23	-3.82	1.08	-8.58	3.51	0.26	4.49	2.50
Interest & Investment Income	-19	-13	-11	-45	0.96	1.08	0.34	1.27	10	9.46	14
Other Income / (Expense), net	2.05	-2.57	11	-18	-3.12	0.78	-9.70	-3.51	-10	-4.98	-12
Income Tax Expense	53	51	75	65	72	74	53	78	98	104	104
Basic Earnings per Share	$1.49	$1.42	$2.04	$1.99	$2.12	$2.35	$2.49	$2.59	$2.38	$2.69	$2.74
Weighted Average Basic Shares Outstanding	147.08M	147.13M	146.96M	147.02M	146.86M	146.81M	146.72M	146.72M	146.18M	145.84M	145.34M
Diluted Earnings per Share	$1.49	$1.42	$2.04	$1.97	$2.11	$2.34	$2.48	$2.58	$2.37	$2.68	$2.74
Weighted Average Diluted Shares Outstanding	147.49M	147.55M	147.45M	147.55M	147.60M	147.48M	147.22M	147.34M	146.90M	146.37M	145.72M
Weighted Average Basic & Diluted Shares Outstanding	147.09M	147.09M	146.91M	146.93M	146.80M	146.87M	146.63M	146.41M	145.97M	145.68M	145.06M
Cash Dividends to Common per Share	$0.48	$0.48	$0.48	$0.48	$0.53	$0.53	$0.53	$0.53	$0.60	$0.60	$0.60

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Net Change in Cash & Equivalents	-163	14	91	-633	-42	316	-168	-22	-46	10	971
Net Cash From Operating Activities	409	548	414	505	459	802	737	351	693	1,401	1,752
Net Cash From Continuing Operating Activities	409	548	414	505	459	802	737	351	693	1,401	1,752
Net Income / (Loss) Continuing Operations	353	352	342	316	405	622	475	779	898	1,021	1,401
Consolidated Net Income / (Loss)	353	352	342	316	405	622	475	779	898	1,021	1,401
Depreciation Expense	73	87	112	120	151	155	157	160	165	177	198
Amortization Expense	-	-	-	0.00	0.00	27	35	34	32	39	37
Non-Cash Adjustments To Reconcile Net Income	48	50	39	60	81	97	69	86	60	119	98
Changes in Operating Assets and Liabilities, net	-65	59	-80	9.47	-177	-98	1.41	-708	-462	45	17
Net Cash From Investing Activities	-143	-1,126	-82	-102	-1,076	-180	-158	-230	-1,160	-270	-200
Net Cash From Continuing Investing Activities	-143	-1,126	-82	-102	-1,076	-180	-158	-230	-1,160	-270	-200
Purchase of Property, Plant & Equipment	-63	-59	-62	-63	-69	-95	-103	-135	-120	-99	-90
Acquisitions	-39	-1,051	-17	-9.78	-960	-39	-53	-64	-1,027	-149	-150
Purchase of Investments	-42	-8.97	-6.46	-29	-47	-32	-22	-21	-32	-13	-6.42
Sale and/or Maturity of Investments	-	-7.10	3.32	-	-	-14	19	-10	19	-8.70	46
Net Cash From Financing Activities	-256	613	-263	-1,027	581	-317	-765	-128	423	-1,119	-606
Net Cash From Continuing Financing Activities	-256	613	-263	-1,027	581	-317	-765	-128	423	-1,119	-606
Repayment of Debt	-182	-284	-545	-1,146	-712	-1,284	-612	-166	-405	-835	-40
Repurchase of Common Equity	-160	-102	-	-54	-23	-	-	0.00	0.00	-150	-300
Payment of Dividends	-158	-169	-198	-200	-213	-225	-230	-245	-261	-284	-312
Issuance of Debt	180	1,140	450	350	1,519	1,190	90	288	1,070	105	0.00
Issuance of Common Equity	39	28	38	39	37	48	38	47	49	53	74
Other Financing Activities, net	25	-	-8.16	-15	-28	-46	-50	-52	-31	-8.76	-29
Effect of Exchange Rate Changes	-173	-21	21	-9.74	-5.56	11	18	-14	-2.15	-1.72	26
Cash Interest Paid	-	11	28	28	36	40	24	22	47	46	28
Cash Income Taxes Paid	49	69	93	171	243	180	221	478	217	278	214

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-19	1.15	28	0.45	188	96	411	277	174	33	243
Net Cash From Operating Activities	286	273	402	440	326	309	579	539	457	340	554
Net Cash From Continuing Operating Activities	286	273	402	440	326	309	579	539	457	340	554
Net Income / (Loss) Continuing Operations	219	209	300	292	311	345	365	380	349	393	399
Consolidated Net Income / (Loss)	219	209	300	292	311	345	365	380	349	393	399
Depreciation Expense	45	45	43	44	45	46	44	64	48	50	59
Amortization Expense	8.51	8.59	11	11	8.98	9.46	8.24	11	9.97	12	10
Non-Cash Adjustments To Reconcile Net Income	23	54	6.08	36	20	23	29	26	26	27	35
Changes in Operating Assets and Liabilities, net	-9.59	-44	41	57	-59	-115	132	59	25	-142	51
Net Cash From Investing Activities	-149	-41	-33	-47	2.15	-37	-32	-134	-53	-51	-58
Net Cash From Continuing Investing Activities	-149	-41	-33	-47	2.15	-37	-32	-134	-53	-51	-58
Purchase of Property, Plant & Equipment	-30	-23	-21	-25	-18	-21	-21	-31	-43	-29	-34
Acquisitions	-114	-8.71	-5.00	-21	-1.77	-3.50	-2.99	-142	-3.34	-6.54	-30
Purchase of Investments	-3.68	-3.63	-2.39	-3.07	-1.35	-20	-2.05	-2.01	-2.17	-4.23	-20
Sale and/or Maturity of Investments	-1.25	-5.46	-4.58	2.58	23	7.42	-5.95	41	-4.10	-12	27
Net Cash From Financing Activities	-151	-239	-336	-393	-151	-148	-144	-164	-230	-258	-255
Net Cash From Continuing Financing Activities	-151	-239	-336	-393	-151	-148	-144	-164	-230	-258	-255
Repurchase of Common Equity	0.00	-50	-50	-50	-50	-75	-75	-100	-150	-175	-175
Payment of Dividends	-72	-71	-70	-72	-79	-78	-78	-78	-88	-88	-87
Issuance of Common Equity	0.98	20	4.89	28	8.38	27	9.02	30	8.21	30	7.43
Other Financing Activities, net	-0.23	-7.80	-0.31	0.87	-0.39	-17	-0.36	-11	-0.72	-20	-0.42
Effect of Exchange Rate Changes	-4.96	8.42	-5.30	0.13	11	-29	7.96	36	-0.07	2.77	2.58
Cash Interest Paid	15	14	11	5.92	7.35	-0.07	14	6.91	6.85	6.61	6.53
Cash Income Taxes Paid	77	97	62	43	106	119	-27	16	62	148	72

This table presents ResMed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Total Assets	2,182	3,257	3,468	3,064	4,108	4,587	4,728	5,096	6,752	6,872	8,174
Total Current Assets	1,408	1,420	1,644	1,066	1,145	1,523	1,575	1,931	2,368	2,358	3,506
Cash & Equivalents	717	731	822	189	147	463	295	274	228	238	1,209
Accounts Receivable	363	382	451	484	528	475	614	576	705	837	939
Inventories, net	247	224	268	269	350	417	457	744	998	822	928
Prepaid Expenses	81	82	103	125	120	75	208	338	437	460	429
Plant, Property, & Equipment, net	388	384	394	387	387	417	463	498	538	548	551
Total Noncurrent Assets	386	1,453	1,430	1,612	2,575	2,647	2,690	2,666	3,846	3,967	4,118
Goodwill	264	1,059	1,065	1,069	1,856	1,890	1,928	1,936	2,770	2,842	3,047
Intangible Assets	47	300	262	215	522	448	393	346	552	486	465
Noncurrent Deferred & Refundable Income Taxes	46	55	62	54	45	41	80	80	133	204	253
Other Noncurrent Operating Assets	28	38	42	274	151	267	289	304	390	435	353
Total Liabilities & Shareholders' Equity	2,182	3,257	3,468	3,064	4,108	4,587	4,728	5,096	6,752	6,872	8,174
Total Liabilities	594	1,562	1,508	1,005	2,035	2,090	1,842	1,735	2,622	2,008	2,207
Total Current Liabilities	266	638	360	511	556	603	912	689	759	911	1,019
Short-Term Debt	-	299	-	11	12	12	12	9.92	9.90	9.90	9.90
Accounts Payable	81	93	93	93	116	136	138	159	151	238	278
Accrued Expenses	133	157	186	186	266	270	321	345	366	378	402
Current Deferred Revenue	36	50	52	61	89	99	110	109	138	153	166
Current Deferred & Payable Income Tax Liabilities	16	39	29	160	73	65	308	45	72	108	132
Other Current Liabilities	-	-	-	-	0.00	21	24	22	22	25	31
Total Noncurrent Liabilities	328	924	1,148	494	1,479	1,488	931	1,046	1,863	1,098	1,187
Long-Term Debt	301	873	1,079	270	1,259	1,164	643	765	1,431	697	658
Noncurrent Deferred Revenue	21	40	53	210	207	200	154	144	156	137	157
Noncurrent Deferred & Payable Income Tax Liabilities	6.37	9.06	14	13	11	13	11	9.71	91	79	78
Other Noncurrent Operating Liabilities	0.00	1.21	2.43	0.92	2.06	110	122	126	185	184	295
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,587	1,695	1,960	2,059	2,072	2,497	2,886	3,361	4,130	4,864	5,968
Total Preferred & Common Equity	1,587	1,695	1,960	2,059	2,072	2,497	2,886	3,361	4,130	4,864	5,968
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,587	1,695	1,960	2,059	2,072	2,497	2,886	3,361	4,130	4,864	5,968
Common Stock	1,229	1,304	1,380	1,451	1,512	1,571	1,623	1,683	1,773	1,897	2,034
Retained Earnings	1,976	2,160	2,316	2,432	2,436	2,833	3,080	3,614	4,253	4,992	6,081
Treasury Stock	-1,445	-1,547	-1,547	-1,600	-1,623	-1,623	-1,623	-1,623	-1,623	-1,773	-2,073
Accumulated Other Comprehensive Income / (Loss)	-174	-223	-189	-224	-253	-284	-193	-313	-273	-252	-75

This table presents ResMed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	9/30/2025	12/31/2025	3/31/2026
Total Assets	6,752	6,741	6,905	6,815	6,872	7,222	7,141	7,567	8,308	8,503	8,784
Total Current Assets	2,368	2,305	2,378	2,351	2,358	2,641	2,836	3,208	3,626	3,819	4,064
Cash & Equivalents	228	209	210	238	238	426	522	933	1,384	1,417	1,661
Accounts Receivable	705	692	730	779	837	811	860	908	907	986	999
Inventories, net	998	958	933	829	822	918	882	863	946	922	912
Prepaid Expenses	437	445	505	505	460	486	572	505	389	494	493
Plant, Property, & Equipment, net	538	534	552	540	548	560	520	535	564	564	567
Total Noncurrent Assets	3,846	3,902	3,975	3,924	3,967	4,021	3,785	3,823	4,119	4,120	4,153
Goodwill	2,770	2,812	2,862	2,836	2,842	2,886	2,805	2,849	3,044	3,044	3,043
Intangible Assets	552	563	528	501	486	479	438	430	447	430	425
Noncurrent Deferred & Refundable Income Taxes	133	138	156	162	204	221	209	217	276	286	313
Other Noncurrent Operating Assets	390	389	429	424	435	436	332	327	352	360	372
Total Liabilities & Shareholders' Equity	6,752	6,741	6,905	6,815	6,872	7,222	7,141	7,567	8,308	8,503	8,784
Total Liabilities	2,622	2,490	2,423	2,185	2,008	2,027	1,888	2,021	2,187	2,182	2,292
Total Current Liabilities	759	771	764	773	911	904	852	941	1,256	1,248	1,351
Short-Term Debt	9.90	9.91	9.90	9.90	9.90	9.90	9.91	9.91	260	260	260
Accounts Payable	151	177	202	177	238	249	220	223	267	250	273
Accrued Expenses	366	348	332	356	378	366	353	386	396	392	446
Current Deferred Revenue	138	147	149	151	153	157	157	160	168	176	179
Current Deferred & Payable Income Tax Liabilities	72	67	47	55	108	94	85	133	135	140	163
Other Current Liabilities	22	22	24	24	25	28	28	29	30	30	29
Total Noncurrent Liabilities	1,863	1,720	1,659	1,412	1,098	1,123	1,036	1,080	932	934	941
Long-Term Debt	1,431	1,352	1,217	997	697	668	663	663	409	404	404
Noncurrent Deferred Revenue	156	134	140	144	137	144	147	151	159	160	163
Noncurrent Deferred & Payable Income Tax Liabilities	91	88	89	87	79	84	77	79	78	78	78
Other Noncurrent Operating Liabilities	185	147	214	184	184	228	150	187	286	293	296
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	4,130	4,250	4,482	4,630	4,864	5,195	5,253	5,546	6,121	6,321	6,492
Total Preferred & Common Equity	4,130	4,250	4,482	4,630	4,864	5,195	5,253	5,546	6,121	6,321	6,492
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	4,130	4,250	4,482	4,630	4,864	5,195	5,253	5,546	6,121	6,321	6,492
Common Stock	1,773	1,792	1,824	1,849	1,897	1,925	1,958	1,991	2,063	2,104	2,135
Retained Earnings	4,253	4,402	4,540	4,770	4,992	5,225	5,492	5,779	6,342	6,647	6,959
Treasury Stock	-1,623	-1,623	-1,673	-1,723	-1,773	-1,823	-1,898	-1,973	-2,223	-2,400	-2,577
Accumulated Other Comprehensive Income / (Loss)	-273	-320	-208	-265	-252	-132	-299	-251	-61	-30	-25

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.97%	9.52%	12.40%	13.23%	11.38%	13.44%	8.11%	11.93%	18.02%	10.95%	9.84%
EBITDA Growth	1.90%	6.59%	4.09%	20.51%	10.12%	36.08%	13.40%	6.77%	14.24%	12.90%	24.67%
EBIT Growth	2.34%	4.43%	-0.93%	24.05%	6.61%	40.27%	15.17%	7.92%	16.65%	13.50%	27.24%
NOPAT Growth	2.11%	3.81%	1.21%	-5.76%	37.71%	52.00%	-29.33%	67.28%	13.60%	15.53%	32.08%
Net Income Growth	2.20%	-0.14%	-2.87%	-7.80%	28.20%	53.65%	-23.67%	64.26%	15.15%	13.75%	37.20%
EPS Growth	3.35%	0.81%	-3.61%	-8.75%	27.85%	52.50%	-24.12%	63.58%	14.91%	13.63%	37.43%
Operating Cash Flow Growth	0.31%	34.02%	-24.43%	21.97%	-9.10%	74.76%	-8.17%	-52.34%	97.44%	102.11%	25.00%
Free Cash Flow Firm Growth	52.10%	-298.00%	143.00%	47.12%	-250.67%	213.51%	-33.16%	-56.57%	-386.21%	292.53%	22.10%
Invested Capital Growth	1.50%	82.48%	3.78%	-2.94%	48.53%	0.44%	1.11%	19.00%	38.34%	-0.19%	1.76%
Revenue Q/Q Growth	2.31%	3.70%	1.88%	2.94%	3.22%	2.26%	3.42%	1.09%	5.16%	2.21%	2.49%
EBITDA Q/Q Growth	-0.68%	6.03%	1.17%	3.54%	-2.48%	15.99%	1.74%	-0.02%	4.47%	4.68%	5.99%
EBIT Q/Q Growth	-0.30%	4.92%	1.21%	3.65%	-4.89%	16.43%	2.09%	0.04%	4.31%	5.53%	5.58%
NOPAT Q/Q Growth	0.76%	0.25%	6.84%	2.56%	-5.51%	16.76%	2.68%	1.51%	2.15%	8.42%	4.84%
Net Income Q/Q Growth	-0.08%	-1.22%	5.71%	2.67%	-9.20%	21.27%	3.78%	-0.01%	4.01%	6.53%	6.66%
EPS Q/Q Growth	0.41%	-0.80%	4.80%	2.82%	-9.09%	20.96%	3.51%	-0.19%	3.92%	6.46%	6.85%
Operating Cash Flow Q/Q Growth	-3.90%	8.43%	-1.48%	-2.11%	2.78%	30.70%	-12.34%	-29.51%	29.50%	16.91%	5.97%
Free Cash Flow Firm Q/Q Growth	-9.37%	-848.63%	155.72%	14.60%	-5.84%	29.79%	-17.27%	-22.41%	11.31%	23.04%	-9.71%
Invested Capital Q/Q Growth	3.55%	53.62%	0.95%	-0.96%	-0.45%	-2.15%	1.13%	2.78%	1.00%	-1.22%	2.65%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	60.24%	58.00%	58.15%	57.04%	57.32%	58.09%	57.53%	56.57%	55.78%	56.67%	59.36%
EBITDA Margin	29.10%	28.32%	26.23%	27.91%	27.60%	33.10%	34.72%	33.12%	32.06%	32.62%	37.03%
Operating Margin	24.38%	23.33%	20.60%	23.15%	22.22%	27.38%	28.27%	27.96%	26.80%	28.17%	32.75%
EBIT Margin	24.75%	23.60%	20.80%	22.79%	21.81%	26.97%	28.73%	27.70%	27.38%	28.01%	32.45%
Profit (Net Income) Margin	21.02%	19.17%	16.56%	13.49%	15.52%	21.02%	14.84%	21.78%	21.25%	21.79%	27.22%
Tax Burden Percent	80.95%	80.17%	81.74%	60.54%	77.98%	84.80%	53.70%	81.15%	81.47%	80.72%	83.50%
Interest Burden Percent	104.92%	101.30%	97.41%	97.75%	91.26%	91.92%	96.21%	96.89%	95.27%	96.38%	100.46%
Effective Tax Rate	19.05%	19.83%	18.26%	39.46%	22.02%	15.20%	46.30%	18.85%	18.53%	19.28%	16.50%
Return on Invested Capital (ROIC)	28.51%	20.80%	15.99%	15.02%	16.89%	21.44%	15.03%	22.84%	20.04%	19.96%	26.16%
ROIC Less NNEP Spread (ROIC-NNEP)	24.28%	89.76%	14.34%	7.91%	9.15%	14.37%	13.03%	15.34%	17.16%	14.67%	44.17%
Return on Net Nonoperating Assets (RNNOA)	-7.41%	0.67%	2.74%	0.69%	2.69%	5.77%	2.60%	2.12%	3.93%	2.74%	-0.29%
Return on Equity (ROE)	21.10%	21.47%	18.73%	15.70%	19.59%	27.21%	17.63%	24.96%	23.96%	22.70%	25.86%
Cash Return on Invested Capital (CROIC)	27.02%	-37.60%	12.28%	18.00%	-22.16%	21.00%	13.93%	5.49%	-12.14%	20.15%	24.41%
Operating Return on Assets (OROA)	18.29%	15.96%	12.78%	16.33%	15.86%	18.34%	19.72%	20.18%	19.52%	19.27%	22.19%
Return on Assets (ROA)	15.54%	12.96%	10.18%	9.66%	11.28%	14.30%	10.19%	15.87%	15.15%	14.99%	18.62%
Return on Common Equity (ROCE)	21.10%	21.47%	18.73%	15.70%	19.59%	27.21%	17.63%	24.96%	23.96%	22.70%	25.86%
Return on Equity Simple (ROE_SIMPLE)	22.23%	20.79%	17.46%	15.33%	19.52%	24.90%	16.44%	23.19%	21.73%	20.99%	0.00%
Net Operating Profit after Tax (NOPAT)	331	344	348	328	452	687	485	812	922	1,065	1,407
NOPAT Margin	19.73%	18.70%	16.84%	14.02%	17.33%	23.22%	15.18%	22.69%	21.84%	22.74%	27.34%
Net Nonoperating Expense Percent (NNEP)	4.23%	-68.96%	1.65%	7.11%	7.75%	7.07%	2.00%	7.50%	2.87%	5.29%	-18.01%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-	21.21%
Cost of Revenue to Revenue	39.76%	42.00%	41.85%	42.96%	42.68%	41.91%	42.47%	43.43%	44.22%	43.33%	40.64%
SG&A Expenses to Revenue	28.51%	26.54%	26.80%	25.65%	24.75%	22.88%	20.97%	20.61%	20.70%	19.57%	19.26%
R&D to Revenue	6.84%	6.45%	6.99%	6.63%	6.93%	6.83%	7.05%	7.09%	6.81%	6.56%	6.44%
Operating Expenses to Revenue	35.87%	34.67%	37.54%	33.89%	35.10%	30.71%	29.26%	28.62%	28.98%	28.50%	26.61%
Earnings before Interest and Taxes (EBIT)	415	434	430	533	569	798	918	991	1,156	1,312	1,670
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	489	521	542	653	719	979	1,110	1,185	1,354	1,529	1,906
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.45	4.76	5.22	6.76	8.07	10.73	12.09	8.94	7.67	5.77	6.34
Price to Tangible Book Value (P/TBV)	5.54	24.01	16.15	17.97	0.00	169.08	61.73	27.85	39.26	18.26	15.40
Price to Revenue (P/Rev)	4.21	4.39	4.95	5.95	6.41	9.06	10.91	8.39	7.50	5.99	7.35
Price to Earnings (P/E)	20.02	22.88	29.90	44.12	41.31	43.12	73.53	38.54	35.31	27.48	27.01
Dividend Yield	2.23%	2.09%	2.25%	1.44%	1.27%	0.84%	0.65%	0.82%	0.82%	1.01%	0.82%
Earnings Yield	5.00%	4.37%	3.34%	2.27%	2.42%	2.32%	1.36%	2.60%	2.83%	3.64%	3.70%
Enterprise Value to Invested Capital (EV/IC)	5.68	3.98	4.73	6.51	5.58	8.57	10.86	7.91	6.16	5.35	6.87
Enterprise Value to Revenue (EV/Rev)	3.96	4.63	5.08	5.99	6.84	9.31	11.03	8.53	7.79	6.09	7.25
Enterprise Value to EBITDA (EV/EBITDA)	13.61	16.33	19.35	21.46	24.80	28.11	31.76	25.77	24.30	18.66	19.57
Enterprise Value to EBIT (EV/EBIT)	16.00	19.60	24.40	26.29	31.38	34.51	38.38	30.81	28.46	21.73	22.33
Enterprise Value to NOPAT (EV/NOPAT)	20.07	24.73	30.14	42.74	39.49	40.08	72.65	37.62	35.68	26.77	26.50
Enterprise Value to Operating Cash Flow (EV/OCF)	16.26	15.52	25.33	27.76	38.86	34.30	47.85	86.97	47.46	20.36	21.29
Enterprise Value to Free Cash Flow (EV/FCFF)	21.17	0.00	39.25	35.65	0.00	40.92	78.43	156.44	0.00	26.52	28.39
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.19	0.69	0.55	0.14	0.61	0.47	0.23	0.23	0.35	0.15	0.11
Long-Term Debt to Equity	0.19	0.52	0.55	0.13	0.61	0.47	0.22	0.23	0.35	0.14	0.11
Financial Leverage	-0.31	0.01	0.19	0.09	0.29	0.40	0.20	0.14	0.23	0.19	-0.01
Leverage Ratio	1.36	1.66	1.84	1.63	1.74	1.90	1.73	1.57	1.58	1.51	1.39
Compound Leverage Factor	1.42	1.68	1.79	1.59	1.58	1.75	1.67	1.52	1.51	1.46	1.40
Debt to Total Capital	15.92%	40.90%	35.49%	12.03%	38.01%	32.02%	18.51%	18.74%	25.87%	12.69%	10.07%
Short-Term Debt to Total Capital	0.00%	10.44%	0.00%	0.49%	0.36%	0.33%	0.34%	0.24%	0.18%	0.18%	0.15%
Long-Term Debt to Total Capital	15.92%	30.46%	35.49%	11.54%	37.66%	31.69%	18.17%	18.50%	25.69%	12.52%	9.92%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	84.08%	59.10%	64.51%	87.97%	61.99%	67.98%	81.49%	81.26%	74.13%	87.31%	89.93%
Debt to EBITDA	0.62	2.25	1.99	0.43	1.77	1.20	0.59	0.65	1.06	0.46	0.35
Net Debt to EBITDA	-0.85	0.85	0.47	0.14	1.56	0.73	0.32	0.42	0.90	0.31	-0.28
Long-Term Debt to EBITDA	0.62	1.68	1.99	0.41	1.75	1.19	0.58	0.65	1.06	0.46	0.35
Debt to NOPAT	0.91	3.41	3.10	0.86	2.81	1.71	1.35	0.96	1.56	0.66	0.47
Net Debt to NOPAT	-1.26	1.28	0.74	0.28	2.49	1.04	0.74	0.62	1.32	0.44	-0.38
Long-Term Debt to NOPAT	0.91	2.54	3.10	0.82	2.79	1.70	1.33	0.94	1.55	0.65	0.47
Altman Z-Score	10.42	5.32	6.45	10.98	7.02	10.02	13.76	13.02	9.61	10.96	13.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.28	2.23	4.57	2.08	2.06	2.53	1.73	2.80	3.12	2.59	3.44
Quick Ratio	4.05	1.75	3.53	1.32	1.22	1.56	1.00	1.23	1.23	1.18	2.11
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	314	-622	267	393	-592	673	449	195	-559	1,076	1,313
Operating Cash Flow to CapEx	654.14%	936.09%	665.48%	807.00%	668.10%	841.56%	717.27%	260.43%	579.33%	1,408.87%	1,949.13%
Free Cash Flow to Firm to Interest Expense	54.33	-55.47	9.47	13.87	-16.39	17.09	19.02	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	70.76	48.90	14.66	17.81	12.70	20.38	31.18	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	59.94	43.67	12.46	15.60	10.80	17.96	26.83	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.74	0.68	0.61	0.72	0.73	0.68	0.69	0.73	0.71	0.69	0.68
Accounts Receivable Turnover	4.65	4.94	4.96	5.01	5.15	5.90	5.87	6.01	6.59	6.08	5.79
Inventory Turnover	3.24	3.28	3.51	3.74	3.60	3.23	3.11	2.59	2.14	2.23	2.39
Fixed Asset Turnover	4.08	4.76	5.31	5.99	6.74	7.35	7.26	7.44	8.15	8.63	9.37
Accounts Payable Turnover	8.02	8.89	9.33	10.84	10.67	9.85	9.92	10.45	12.05	10.45	8.11
Days Sales Outstanding (DSO)	78.50	73.91	73.52	72.85	70.87	61.91	62.17	60.71	55.35	60.07	63.01
Days Inventory Outstanding (DIO)	112.72	111.39	103.97	97.49	101.44	112.89	117.47	141.05	170.24	163.64	152.71
Days Payable Outstanding (DPO)	45.53	41.05	39.10	33.67	34.19	37.04	36.80	34.91	30.30	34.93	45.02
Cash Conversion Cycle (CCC)	145.69	144.25	138.39	136.67	138.11	137.76	142.84	166.85	195.30	188.79	170.70
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,171	2,136	2,217	2,152	3,196	3,210	3,246	3,862	5,343	5,333	5,427
Invested Capital Turnover	1.44	1.11	0.95	1.07	0.97	0.92	0.99	1.01	0.92	0.88	0.96
Increase / (Decrease) in Invested Capital	17	966	81	-65	1,044	14	36	617	1,481	-10	94
Enterprise Value (EV)	6,647	8,505	10,490	14,018	17,839	27,518	35,252	30,537	32,904	28,523	37,289
Market Capitalization	7,064	8,063	10,233	13,925	16,715	26,805	34,892	30,036	31,691	28,054	37,830
Book Value per Share	$11.26	$12.07	$13.82	$14.42	$14.45	$17.26	$19.83	$22.97	$28.11	$33.11	$40.70
Tangible Book Value per Share	$9.05	$2.39	$4.47	$5.43	($2.14)	$1.10	$3.88	$7.37	$5.49	$10.46	$16.75
Total Capital	1,888	2,868	3,039	2,340	3,343	3,673	3,541	4,136	5,571	5,571	6,636
Total Debt	301	1,173	1,079	281	1,271	1,176	655	775	1,441	707	668
Total Long-Term Debt	301	873	1,079	270	1,259	1,164	643	765	1,431	697	658
Net Debt	-417	441	257	93	1,124	713	360	502	1,213	469	-541
Capital Expenditures (CapEx)	63	59	62	63	69	95	103	135	120	99	90
Debt-free, Cash-free Net Working Capital (DFCFNWC)	424	350	462	377	454	470	380	978	1,391	1,219	1,287
Debt-free Net Working Capital (DFNWC)	1,141	1,081	1,284	566	601	933	675	1,252	1,619	1,457	2,496
Net Working Capital (NWC)	1,141	782	1,284	554	589	921	663	1,242	1,609	1,447	2,486
Net Nonoperating Expense (NNE)	-22	-8.51	5.77	12	47	65	11	32	25	44	6.51
Net Nonoperating Obligations (NNO)	-417	441	257	93	1,124	713	360	502	1,213	469	-541
Total Depreciation and Amortization (D&A)	73	87	112	120	151	181	192	194	198	216	236
Debt-free, Cash-free Net Working Capital to Revenue	25.26%	19.02%	22.35%	16.12%	17.43%	15.88%	11.88%	27.34%	32.95%	26.01%	25.01%
Debt-free Net Working Capital to Revenue	67.98%	58.80%	62.12%	24.18%	23.07%	31.54%	21.11%	34.99%	38.34%	31.10%	48.51%
Net Working Capital to Revenue	67.98%	42.52%	62.12%	23.69%	22.61%	31.14%	20.74%	34.72%	38.11%	30.89%	48.32%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.51	$2.51	$2.42	$2.21	$2.83	$4.31	$3.27	$5.34	$6.12	$6.94	$9.55
Adjusted Weighted Average Basic Shares Outstanding	140.47M	140.24M	141.36M	142.76M	143.11M	144.34M	145.31M	146.07M	146.77M	147.02M	146.72M
Adjusted Diluted Earnings per Share	$2.47	$2.49	$2.40	$2.19	$2.80	$4.27	$3.24	$5.30	$6.09	$6.92	$9.51
Adjusted Weighted Average Diluted Shares Outstanding	142.69M	141.67M	142.45M	143.99M	144.48M	145.65M	146.45M	147.04M	147.46M	147.55M	147.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	140.52M	140.70M	142.21M	142.68M	143.67M	144.90M	145.68K	146.42M	147.07M	146.93M	146.41M
Normalized Net Operating Profit after Tax (NOPAT)	331	349	373	339	491	686	490	813	939	1,117	1,407
Normalized NOPAT Margin	19.73%	19.00%	18.06%	14.49%	18.84%	23.20%	15.32%	22.73%	22.23%	23.85%	27.34%
Pre Tax Income Margin	25.96%	23.91%	20.26%	22.28%	19.91%	24.79%	27.64%	26.84%	26.09%	27.00%	32.60%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	71.91	38.72	15.23	18.81	15.72	20.26	38.87	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	57.34	30.69	12.33	11.57	12.49	17.45	20.54	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	61.09	33.50	13.02	16.60	13.82	17.84	34.53	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	46.52	25.47	10.12	9.36	10.59	15.02	16.19	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	44.69%	48.06%	57.85%	63.37%	52.55%	36.26%	48.52%	31.48%	29.04%	27.78%	22.26%
Augmented Payout Ratio	90.12%	77.02%	57.85%	80.42%	58.20%	36.26%	48.52%	31.48%	29.04%	42.47%	43.67%

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	145,678,401.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	145,678,401.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	2.74
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	16.00%	12.48%	7.17%	9.01%	11.08%	10.26%	7.92%	10.20%	9.07%	10.98%	10.81%
EBITDA Growth	9.36%	-1.96%	23.32%	19.58%	27.12%	45.42%	6.32%	25.81%	12.85%	15.84%	18.97%
EBIT Growth	7.41%	-5.00%	26.76%	23.41%	32.01%	53.39%	7.92%	24.32%	13.62%	16.43%	17.22%
NOPAT Growth	5.09%	-3.85%	24.11%	36.36%	34.98%	55.26%	24.25%	20.99%	10.78%	13.18%	6.50%
Net Income Growth	4.25%	-7.16%	29.24%	27.25%	41.90%	65.05%	21.48%	29.93%	11.94%	13.92%	9.23%
EPS Growth	4.20%	-7.19%	29.11%	27.10%	41.61%	64.79%	21.57%	30.96%	12.32%	14.53%	10.48%
Operating Cash Flow Growth	541.00%	112.10%	42.28%	85.36%	13.71%	13.12%	43.93%	22.42%	40.48%	10.08%	-4.24%
Free Cash Flow Firm Growth	-371.13%	100.61%	114.82%	125.68%	123.59%	4,977.63%	153.50%	-12.03%	43.35%	-48.60%	-61.30%
Invested Capital Growth	34.36%	4.03%	2.05%	-0.19%	0.80%	-1.72%	-2.08%	1.76%	-0.74%	3.03%	3.95%
Revenue Q/Q Growth	-1.76%	5.49%	2.94%	2.19%	0.11%	4.70%	0.75%	4.36%	-0.92%	6.53%	0.60%
EBITDA Q/Q Growth	-1.34%	-5.40%	35.21%	-5.24%	4.88%	8.22%	-1.15%	12.13%	-5.93%	11.10%	1.52%
EBIT Q/Q Growth	-1.00%	-6.36%	41.64%	-6.02%	5.90%	8.80%	-0.35%	8.27%	-3.22%	11.49%	0.33%
NOPAT Q/Q Growth	2.01%	-4.97%	35.43%	3.87%	0.97%	9.31%	8.38%	1.14%	-7.55%	11.69%	1.98%
Net Income Q/Q Growth	-4.46%	-4.84%	43.91%	-2.75%	6.54%	10.68%	5.93%	4.02%	-8.21%	12.64%	1.56%
EPS Q/Q Growth	-3.87%	-4.70%	43.66%	-3.43%	7.11%	10.90%	5.98%	4.03%	-8.14%	13.08%	2.24%
Operating Cash Flow Q/Q Growth	20.57%	-4.70%	47.35%	9.47%	-26.03%	-5.20%	87.50%	-6.89%	-15.12%	-25.71%	63.10%
Free Cash Flow Firm Q/Q Growth	8.29%	100.75%	2,117.28%	68.12%	-15.75%	61.69%	10.70%	-41.66%	37.29%	-42.02%	-16.66%
Invested Capital Q/Q Growth	1.11%	1.77%	-1.81%	-1.22%	2.12%	-0.78%	-2.17%	2.65%	-0.38%	2.99%	-1.30%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.44%	55.64%	57.88%	58.50%	58.57%	58.60%	59.33%	60.84%	61.46%	61.76%	62.25%
EBITDA Margin	31.25%	28.03%	36.81%	34.14%	35.76%	36.96%	36.27%	38.97%	37.00%	38.59%	38.94%
Operating Margin	26.22%	23.66%	31.29%	31.17%	31.63%	32.54%	33.00%	33.72%	33.43%	34.56%	34.92%
EBIT Margin	26.40%	23.44%	32.25%	29.66%	31.38%	32.60%	32.25%	33.46%	32.68%	34.21%	34.11%
Profit (Net Income) Margin	19.91%	17.96%	25.10%	23.89%	25.43%	26.88%	28.26%	28.17%	26.10%	27.59%	27.86%
Tax Burden Percent	80.61%	80.48%	80.04%	81.69%	81.19%	82.38%	87.39%	82.90%	78.01%	79.13%	79.38%
Interest Burden Percent	93.52%	95.21%	97.26%	98.61%	99.82%	100.07%	100.27%	101.56%	102.36%	101.94%	102.87%
Effective Tax Rate	19.39%	19.52%	19.96%	18.31%	18.81%	17.62%	12.61%	17.10%	21.99%	20.87%	20.62%
Return on Invested Capital (ROIC)	19.62%	15.90%	21.48%	22.35%	22.76%	24.23%	27.11%	26.74%	25.27%	26.91%	28.47%
ROIC Less NNEP Spread (ROIC-NNEP)	18.07%	14.92%	21.55%	20.07%	22.32%	24.38%	24.16%	18.68%	25.18%	25.73%	28.16%
Return on Net Nonoperating Assets (RNNOA)	4.09%	4.65%	5.35%	3.75%	3.32%	2.92%	1.21%	-0.12%	-1.03%	-1.34%	-2.94%
Return on Equity (ROE)	23.72%	20.56%	26.84%	26.10%	26.08%	27.16%	28.32%	26.61%	24.24%	25.57%	25.53%
Cash Return on Invested Capital (CROIC)	-9.51%	13.20%	16.36%	20.15%	20.34%	25.02%	27.23%	24.41%	27.30%	24.10%	24.15%
Operating Return on Assets (OROA)	19.38%	15.55%	21.86%	20.40%	21.60%	22.87%	22.52%	22.89%	22.13%	23.61%	23.11%
Return on Assets (ROA)	14.61%	11.91%	17.01%	16.43%	17.51%	18.86%	19.73%	19.27%	17.67%	19.04%	18.87%
Return on Common Equity (ROCE)	23.72%	20.56%	26.84%	26.10%	26.08%	27.16%	28.32%	26.61%	24.24%	25.57%	25.53%
Return on Equity Simple (ROE_SIMPLE)	21.33%	19.87%	20.70%	0.00%	21.42%	23.77%	23.68%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	233	221	300	311	314	344	373	377	348	389	397
NOPAT Margin	21.13%	19.04%	25.05%	25.46%	25.68%	26.81%	28.84%	27.95%	26.08%	27.34%	27.72%
Net Nonoperating Expense Percent (NNEP)	1.56%	0.98%	-0.06%	2.28%	0.44%	-0.15%	2.94%	8.06%	0.09%	1.18%	0.32%
Return On Investment Capital (ROIC_SIMPLE)	-	3.88%	-	-	-	5.80%	5.99%	5.68%	5.13%	5.57%	5.54%
Cost of Revenue to Revenue	45.56%	44.36%	42.12%	41.50%	41.43%	41.40%	40.67%	39.16%	38.54%	38.24%	37.76%
SG&A Expenses to Revenue	20.22%	19.11%	19.21%	19.80%	19.52%	18.85%	18.99%	19.67%	19.41%	19.57%	19.96%
R&D to Revenue	6.87%	6.35%	6.44%	6.61%	6.49%	6.35%	6.50%	6.41%	6.54%	6.39%	6.59%
Operating Expenses to Revenue	28.22%	31.98%	26.58%	27.33%	26.94%	26.05%	26.33%	27.12%	28.02%	27.20%	27.33%
Earnings before Interest and Taxes (EBIT)	291	273	386	363	384	418	417	451	437	487	488
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	344	326	441	418	438	474	468	525	494	549	557
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.06	5.59	6.26	5.77	6.90	6.39	5.93	6.34	6.55	5.56	5.04
Price to Tangible Book Value (P/TBV)	24.60	22.96	22.43	18.26	19.60	16.70	14.50	15.40	15.24	12.35	10.82
Price to Revenue (P/Rev)	4.92	5.57	6.32	5.99	7.46	6.81	6.55	7.35	7.62	6.51	5.91
Price to Earnings (P/E)	23.74	28.15	30.25	27.48	32.23	26.88	25.03	27.01	27.87	23.66	21.52
Dividend Yield	1.23%	1.08%	0.95%	1.01%	0.81%	0.88%	0.92%	0.82%	0.80%	0.94%	1.04%
Earnings Yield	4.21%	3.55%	3.31%	3.64%	3.10%	3.72%	3.99%	3.70%	3.59%	4.23%	4.65%
Enterprise Value to Invested Capital (EV/IC)	4.20	4.74	5.51	5.35	6.63	6.24	6.17	6.87	7.28	6.18	5.77
Enterprise Value to Revenue (EV/Rev)	5.18	5.79	6.49	6.09	7.51	6.84	6.50	7.25	7.49	6.37	5.73
Enterprise Value to EBITDA (EV/EBITDA)	16.39	18.95	20.38	18.66	22.27	19.05	18.14	19.57	20.06	16.89	14.91
Enterprise Value to EBIT (EV/EBIT)	19.28	22.45	23.93	21.73	25.70	21.74	20.62	22.33	22.86	19.21	17.02
Enterprise Value to NOPAT (EV/NOPAT)	24.29	28.21	30.29	26.77	31.49	26.57	24.30	26.50	27.32	23.15	20.98
Enterprise Value to Operating Cash Flow (EV/OCF)	24.25	24.17	24.83	20.36	25.07	22.84	19.73	21.29	20.90	17.97	16.78
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	36.64	34.04	26.52	32.73	24.73	22.42	28.39	26.58	26.02	24.35
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.32	0.27	0.22	0.15	0.13	0.13	0.12	0.11	0.11	0.11	0.10
Long-Term Debt to Equity	0.32	0.27	0.22	0.14	0.13	0.13	0.12	0.11	0.07	0.06	0.06
Financial Leverage	0.23	0.31	0.25	0.19	0.15	0.12	0.05	-0.01	-0.04	-0.05	-0.10
Leverage Ratio	1.55	1.65	1.58	1.51	1.48	1.44	1.41	1.39	1.37	1.35	1.36
Compound Leverage Factor	1.45	1.57	1.54	1.49	1.48	1.44	1.42	1.41	1.40	1.38	1.40
Debt to Total Capital	24.26%	21.49%	17.86%	12.69%	11.54%	11.35%	10.82%	10.07%	9.85%	9.50%	9.28%
Short-Term Debt to Total Capital	0.18%	0.17%	0.18%	0.18%	0.17%	0.17%	0.16%	0.15%	3.83%	3.72%	3.63%
Long-Term Debt to Total Capital	24.08%	21.32%	17.69%	12.52%	11.37%	11.19%	10.66%	9.92%	6.02%	5.78%	5.65%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	75.74%	78.51%	82.14%	87.31%	88.46%	88.65%	89.18%	89.93%	90.15%	90.50%	90.72%
Debt to EBITDA	0.98	0.89	0.69	0.46	0.42	0.38	0.37	0.35	0.34	0.33	0.31
Net Debt to EBITDA	0.83	0.74	0.53	0.31	0.15	0.09	-0.14	-0.28	-0.36	-0.37	-0.47
Long-Term Debt to EBITDA	0.98	0.88	0.68	0.46	0.41	0.37	0.37	0.35	0.21	0.20	0.19
Debt to NOPAT	1.46	1.33	1.02	0.66	0.59	0.53	0.50	0.47	0.46	0.45	0.44
Net Debt to NOPAT	1.23	1.10	0.78	0.44	0.22	0.12	-0.19	-0.38	-0.50	-0.51	-0.66
Long-Term Debt to NOPAT	1.45	1.32	1.01	0.65	0.58	0.52	0.49	0.47	0.28	0.27	0.27
Altman Z-Score	7.16	8.19	10.08	10.51	12.76	12.96	12.04	12.50	13.21	11.95	10.85
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.99	3.11	3.04	2.59	2.92	3.33	3.41	3.44	2.89	3.06	3.01
Quick Ratio	1.17	1.23	1.32	1.18	1.37	1.62	1.96	2.11	1.82	1.93	1.97
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,149	8.63	191	322	271	438	485	283	388	225	188
Operating Cash Flow to CapEx	953.16%	1,168.30%	1,897.18%	1,768.88%	1,824.76%	1,494.98%	2,782.56%	1,761.54%	1,064.40%	1,190.46%	1,646.56%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	17.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	36.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	34.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.73	0.66	0.68	0.69	0.69	0.70	0.70	0.68	0.68	0.69	0.68
Accounts Receivable Turnover	6.66	6.43	6.26	6.08	6.39	6.20	5.95	5.79	6.12	5.85	5.81
Inventory Turnover	2.15	2.10	2.20	2.23	2.17	2.26	2.45	2.39	2.25	2.34	2.40
Fixed Asset Turnover	8.57	8.38	8.58	8.63	8.79	9.19	9.34	9.37	9.36	9.96	10.05
Accounts Payable Turnover	10.93	10.15	11.95	10.45	9.55	9.70	10.36	8.11	8.13	8.97	8.58
Days Sales Outstanding (DSO)	54.77	56.81	58.34	60.07	57.08	58.89	61.31	63.01	59.65	62.40	62.83
Days Inventory Outstanding (DIO)	169.74	173.49	165.73	163.64	168.26	161.61	149.10	152.71	162.06	155.89	152.24
Days Payable Outstanding (DPO)	33.38	35.96	30.55	34.93	38.23	37.63	35.25	45.02	44.87	40.67	42.54
Cash Conversion Cycle (CCC)	191.13	194.34	193.52	188.79	187.10	182.86	175.17	170.70	176.84	177.61	172.54
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,403	5,498	5,399	5,333	5,446	5,404	5,286	5,427	5,406	5,568	5,495
Invested Capital Turnover	0.93	0.84	0.86	0.88	0.89	0.90	0.94	0.96	0.97	0.98	1.03
Increase / (Decrease) in Invested Capital	1,382	213	108	-10	43	-94	-113	94	-40	164	209
Enterprise Value (EV)	22,676	26,085	29,763	28,523	36,120	33,722	32,616	37,289	39,363	34,406	31,705
Market Capitalization	21,524	25,069	28,994	28,054	35,869	33,571	32,876	37,830	40,078	35,159	32,702
Book Value per Share	$28.90	$30.47	$31.48	$33.11	$35.36	$35.78	$37.76	$40.70	$41.81	$43.30	$44.56
Tangible Book Value per Share	$5.95	$7.42	$8.79	$10.46	$12.46	$13.69	$15.44	$16.75	$17.96	$19.50	$20.76
Total Capital	5,612	5,709	5,637	5,571	5,873	5,926	6,219	6,636	6,790	6,985	7,156
Total Debt	1,361	1,227	1,007	707	677	673	673	668	669	664	664
Total Long-Term Debt	1,352	1,217	997	697	668	663	663	658	409	404	404
Net Debt	1,152	1,016	769	469	251	151	-260	-541	-715	-753	-996
Capital Expenditures (CapEx)	30	23	21	25	18	21	21	31	43	29	34
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,335	1,414	1,350	1,219	1,321	1,472	1,345	1,287	1,246	1,414	1,312
Debt-free Net Working Capital (DFNWC)	1,544	1,624	1,588	1,457	1,747	1,994	2,278	2,496	2,630	2,831	2,973
Net Working Capital (NWC)	1,534	1,614	1,578	1,447	1,737	1,984	2,268	2,486	2,370	2,571	2,713
Net Nonoperating Expense (NNE)	14	13	-0.67	19	3.10	-0.89	7.49	-2.91	-0.20	-3.55	-1.99
Net Nonoperating Obligations (NNO)	1,152	1,016	769	469	251	151	-260	-541	-715	-753	-996
Total Depreciation and Amortization (D&A)	53	53	55	55	54	56	52	74	58	62	69
Debt-free, Cash-free Net Working Capital to Revenue	30.50%	31.39%	29.45%	26.01%	27.47%	29.88%	26.79%	25.01%	23.71%	26.19%	23.70%
Debt-free Net Working Capital to Revenue	35.28%	36.05%	34.64%	31.10%	36.34%	40.48%	45.36%	48.51%	50.03%	52.44%	53.68%
Net Working Capital to Revenue	35.06%	35.83%	34.43%	30.89%	36.13%	40.27%	45.16%	48.32%	45.08%	47.62%	48.99%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.49	$1.42	$2.04	$1.99	$2.12	$2.35	$2.49	$2.59	$2.38	$2.69	$2.74
Adjusted Weighted Average Basic Shares Outstanding	147.08M	147.13M	146.96M	147.02M	146.86M	146.81M	146.72M	146.72M	146.18M	145.84M	145.34M
Adjusted Diluted Earnings per Share	$1.49	$1.42	$2.04	$1.97	$2.11	$2.34	$2.48	$2.58	$2.37	$2.68	$2.74
Adjusted Weighted Average Diluted Shares Outstanding	147.49M	147.55M	147.45M	147.55M	147.60M	147.48M	147.22M	147.34M	146.90M	146.37M	145.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	147.09M	147.09M	146.91M	146.93M	146.80M	146.87M	146.63M	146.41M	145.97M	145.68M	145.06M
Normalized Net Operating Profit after Tax (NOPAT)	233	273	300	311	314	344	373	377	361	394	397
Normalized NOPAT Margin	21.13%	23.48%	25.05%	25.46%	25.68%	26.81%	28.84%	27.95%	27.00%	27.67%	27.72%
Pre Tax Income Margin	24.69%	22.31%	31.36%	29.25%	31.32%	32.63%	32.34%	33.98%	33.45%	34.87%	35.09%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	35.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	27.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	33.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	25.27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	29.57%	30.80%	29.09%	27.78%	26.10%	23.82%	23.20%	22.26%	22.31%	22.25%	22.39%
Augmented Payout Ratio	29.57%	36.42%	39.53%	42.47%	44.07%	41.84%	42.24%	43.67%	50.13%	55.91%	61.87%

Financials Breakdown Chart

Key Financial Trends

Based on ResMed (NYSE: RMD) quarterly cash flow statements, income statements, and balance sheets from the last four years, here are the most relevant trends and takeaways for retail investors. The items below are grouped to highlight positives first, then neutral items, and finally negatives.

Strong latest-quarter revenue and improved margins: In Q2 2026, operating revenue was $1,422,808,000 with gross profit of $878,724,000, implying a gross margin of about 61.7%. This suggests healthy scale and improving profitability relative to earlier years.
Net income and EPS rising in the latest period: Q2 2026 net income from continuing operations was $392,593,000, with diluted earnings per share of $2.68, up from the prior-year level in Q2 2025 (net income $344,622,000; diluted EPS $2.37).
Robust operating cash flow across recent quarters: ResMed has generated strong cash from operations in multiple quarters, including CFO of $578,661,000 in Q3 2025 and $538,766,000 in Q4 2025, underscoring the company’s ability to fund dividends and buybacks from operating cash flow.
Shareholder returns showing discipline: Cash dividends per share were $0.60 in Q1 2026 and Q2 2026, indicating a steady payout policy. In addition, ResMed has engaged in share repurchases (e.g., $150.0M in Q1 2026 and $175.0M in Q2 2026), supporting earnings per share growth via lower share count.
Strong balance sheet and liquidity: As of Q2 2026, cash & equivalents were about $1.42B, total equity around $6.32B, and total assets near $8.50B, signaling ample liquidity and a solid capital base to weather cyclical pressures.
Modest but effective capital deployment (free cash flow potential): With operating cash flow typically in the hundreds of millions per quarter and relatively modest quarterly capital expenditures (e.g., capex in the $28–29M range in recently reported quarters), ResMed appears capable of funding dividends and buybacks while investing for growth.
Debt levels are moderate and manageable: Long-term debt tends to be in the low-to-mid hundreds of millions, with no clear near-term maturity pressure observed in the provided data. This supports a comfortable debt profile relative to the scale of the business.
Restatements and annualization notes: Some quarters show restated or calculated figures (for example certain Q1/Q2 2025 entries and other periods). Cross-year comparisons should consider filing disclosures and restatements.
Investing activities are typically negative: Net cash from continuing investing activities and overall investing cash flows are negative in many quarters due to acquisitions, investments, and capital expenditures, which is common for a growth-focused company and contributes to a growing asset base.
Financing cash outflows remain a headwind at times: Net cash from financing activities has been negative in several quarters due to ongoing share repurchases and dividend payments, which reduce cash on hand (for example, Q2 2026 net financing cash flow around -$258.3M; Q4 2025 around -$163.9M).

Overall, ResMed shows durable profitability, solid cash-flow generation, and active capital returns to shareholders, supported by a strong balance sheet. As always, investors should watch long-term trends in revenue growth, gross margins, and the sustainability of ongoing buybacks and dividends in relation to debt levels and reinvestment needs.

05/22/26 01:26 PM ETAI Generated. May Contain Errors.

ResMed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ResMed's fiscal year ends in June. Their fiscal year 2025 ended on June 30, 2025.

ResMed's net income appears to be on an upward trend, with a most recent value of $1.40 billion in 2025, rising from $352.89 million in 2015. The previous period was $1.02 billion in 2024. Find out what analysts predict for ResMed in the coming months.

ResMed's total operating income in 2025 was $1.69 billion, based on the following breakdown:

Total Gross Profit: $3.05 billion
Total Operating Expenses: $1.37 billion

Over the last 10 years, ResMed's total revenue changed from $1.68 billion in 2015 to $5.15 billion in 2025, a change of 206.5%.

ResMed's total liabilities were at $2.21 billion at the end of 2025, a 9.9% increase from 2024, and a 271.2% increase since 2015.

In the past 10 years, ResMed's cash and equivalents has ranged from $147.13 million in 2019 to $1.21 billion in 2025, and is currently $1.21 billion as of their latest financial filing in 2025.

Over the last 10 years, ResMed's book value per share changed from 11.26 in 2015 to 40.70 in 2025, a change of 261.3%.

Related Companies

Financial statements for NYSE:RMD last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Financials

Financials Breakdown Chart

Key Financial Trends

ResMed Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ResMed (RMD) Financials

Annual Income Statements for ResMed

Quarterly Income Statements for ResMed

Annual Cash Flow Statements for ResMed

Quarterly Cash Flow Statements for ResMed

Annual Balance Sheets for ResMed

Quarterly Balance Sheets for ResMed

Annual Metrics And Ratios for ResMed

Quarterly Metrics And Ratios for ResMed

Financials Breakdown Chart

Key Financial Trends

ResMed Financials - Frequently Asked Questions

When does ResMed's financial year end?

How has ResMed's net income changed over the last 10 years?

What is ResMed's operating income?

How has ResMed's revenue changed over the last 10 years?

How much debt does ResMed have?

How much cash does ResMed have?

How has ResMed's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools